MIG SPRAY : Specific natural preventive treatment for migraines
MIGSPRAY is an innovative, nasally-applied medical product designed to alleviate the symptoms of migraines. It works by using an osmotic mechanism to draw out fluids from the highly vascular nasal cavity, along with key proteins involved in triggering migraines.
The MIGSPRAY’s glycerol film then traps these proteins, reducing their potential to cause a migraine. Furthermore, MIGSPRAY’s osmotic action assists in cleaning the nasal cavity and sinuses, a feature that is beneficial considering the role of nasal congestion in migraines.
Its effectiveness and safety have been confirmed through two clinical studies, showing efficacy from the second month of treatment and reporting no severe adverse effects.
MIG SPRAY Class IIa medical device
MIGSPRAY is an innovative preventive treatment for migraines, using a nasal spray format. This device acts through a unique osmotic mechanism and targets the proteins involved in the occurrence and development of migraine attacks.
MIG SPRAY was developed in collaboration with the European migraine research center NEURO-DOL (Inserm, CHU de Clermont-Ferrand).
Product development and research
MIGSPRAY was developed based on extensive research on the role of proteins in migraine pathogenesis. The product is specifically designed to target proteins such as CGRP, interleukins 6 and 12, or TNF α, which have been implicated in the onset of migraines. It is formulated to exert an osmotic effect, drawing these proteins away from the nasal lining into an osmotically active solution. Furthermore, the osmotic action of the spray helps clean the nasal cavity and sinuses, which can also aid in relieving the symptoms of migraines.
Mode of action
1 > Protective barrier
Migraine patients are sensitive to contaminants, allergens, odors, chemical molecules, etc. that can trigger an attack. The film created by MIG SPRAY acts as a protective barrier.
2 > Effect on migraine proteins
The osmotic action created by the film attracts CGRP and interleukins present in the nasal bloodstream. Gradually, the concentration decreases and limits the intensity of migraines.
3 > Promotes oxygenation
The osmotic action allows to drain the sinuses and to decongest the nose. This effect allows a better oxygenation of the brain and limits the occurrence of attacks.
MIGSPRAY is a promising preventive treatment for migraines. Its unique mechanism of action, combined with clinical evidence demonstrating its efficacy and safety, make it a valuable addition to the therapeutic options for migraine management. Future research can further shed light on its potential applications and benefits.
2nd most disabling disease in the world
Migraines are a common and often debilitating neurological condition characterized by severe, throbbing headaches typically occurring on one side of the head. They are one of the most prevalent health conditions worldwide, affecting about 20% of the population.
Migraines are not just an ordinary headache. They are often accompanied by an array of symptoms, including sensitivity to light and sound, nausea, vomiting, and disturbances in vision known as ‘auras’. Migraines can last for hours or even days, and the intensity and duration can vary significantly from one person to another.
Migraine is the 3rd most common disease
3rd most common disease in the world according to the World Health Organization (WHO).
More common than :
- Diabetes
- Asthma
- Heart disease
The exact cause of migraines remains unclear, but they are believed to result from abnormal brain activity affecting nerve signals, chemicals, and blood vessels in the brain. It’s commonly agreed upon that certain factors such as hormonal changes, certain foods and drinks, stress, and changes in sleep pattern can trigger migraines.
A major impact on the daily lives of those affected
Migraines are ranked as the second most disabling illness globally, only behind lower back pain. They can significantly impact an individual’s quality of life, affecting their daily activities, work productivity, and overall wellbeing.
Despite the high prevalence and severity of migraines, they are often underdiagnosed and undertreated. Many people with migraines do not seek medical attention, and even when they do, they may not receive the appropriate treatment.
The goal of migraine treatment is to prevent attacks, relieve symptoms, and improve the individual’s quality of life. The development of new therapeutic strategies and treatments, such as MIGSPRAY, offers hope for more effective management of this debilitating condition.
CLAIMS IN LINE WITH THE NEW REGULATION
- Reduces the frequency and intensity of attacks
- Preventive treatment against migraine
- Mechanical mode of action
- Instant osmotic action
- Compatible with your usual treatments
- Improves quality of life
- No drowsiness
- Non-addictive
MIG SPRAY Randomized, double-blind clinical trial
General informations
Title : Preventing migraine by reducing nasal surface contaminants & restoring nasal mucosa integrity: Clinical efficacy of a new generation of polymeric osmotic treatment- MIG SPRAY
Journal : Clincal Investigation | Clin. Invest. (Euro.) (2023) 13(1), 316-326
Patients: N=129 | Test product = 65 ; Comparator = 64
Duration : 1 month baseline + 3 month treatment
Inclusion : Patients having episodic migraine and diagnosed for more than a year for migraines without aura and meeting the migraine criteria as defined in the International Classification of Headache Disorder (ICHD-3 :1.1).
Link to the publication
Main results
FREQUENCY
- 25% fewer migraine days per month after 2 months of treatment*
Propranolol, the most widely prescribed prophylactic drug, reduces the frequency of attacks by an average of 30%.
OTHER PARAMETERS
- 40% reduction in crisis intensity*
MIDAS test : Migraine disability assessment - 71% of patients satisfied
Clinical study in children
A second clinical study in children is currently underway. This study will enable MIG SPRAY to be used from the age of 3, with an adapted dosage. Results expected in 2024
| Indication | Filmogen liquid bandage for the prevention of migraine. |
| Composition | Filmogenic glycerol, water, association of Vitris vinifera, Curcuma longa, Tanacetum parthenium, Salix alba and Mentha piperita, potassium sorbate, sodium and citric acid. |
| Presentation | Nasal spray 15ml |
| Class | MDD Class I | MDR Class IIa |
| Direction | Apply 2 sprays in each nostril, 2-3 times a day |
| Precautions | For topical use only (nasal cavity). Keep out of reach and sight of children. |
| Age | 18+ |
| Storage conditions | Below 25°C |
| Legal manufacturer | VITROBIO (France) |
| Product code | MIG |